secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRISPR Therapeutics AG (CRSP)
CIK:        0001674416
Form:       8-K
Filed at:   2025-05-19T23:59:59+00:00
Accession:  0000950170-25-074428
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CRISPR Therapeutics enters collaboration with Sirius on FXI-targeting siRNA; positive Phase 1 data
--------------------------------------------------------------------------------

- Upfront consideration: $70M in common shares + $25M cash to Sirius for co-development of FXI-targeting siRNA SRSD107.
- Potential milestones: up to $340M for opt-out and up to $87.5M for development/regulatory; royalties mid-single to low-double digit.
- Phase 1: single doses well tolerated, >93% reduction in FXI levels and activity, sustained up to six months post-dosing.
- Phase 2 trial initiated for prevention of venous thromboembolism in patients undergoing total knee arthroplasty.
- Company has options to exclusively license Sirius siRNA technology for up to two additional targets; $10M option fee per target.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674416/000095017025074428/0000950170-25-074428-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674416/000095017025074428/crsp-20250519.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-074428

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer